SEGMENTED INFORMATION

9 Months Ended

Sep. 30, 2024

SEGMENTED INFORMATION

SEGMENTED INFORMATION

NOTE 11 – SEGMENTED INFORMATION

At September 30, 2024, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia (formerly known as Bionexus Gene Lab Sdn. Bhd.) and Chemrex.

	BioNexus Gene Lab Corp.
	a Wyoming company
100% owned		100% owned
MRNA Scientific Sdn. Bhd. (formerly “Bionexus Gene Lab Sdn. Bhd.”), a Malaysian company		Chemrex Corporation Sdn. Bhd., a Malaysian Company

At September 30, 2024, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex Corporation.

For the nine months ended September 30, 2024, segmented (unaudited) revenue and net (loss)/profit (Currency expressed in United States Dollars (“US$”) are as follows:

	MRNA Scientific			Chemrex Corporation			BGLC			Total
	Nine months ended September 30, 2024
REVENUE	$	11,224		$	6,975,567		$	-		$	6,986,791
COST OF REVENUE		(6,723	)		(5,999,781	)		-			(6,006,504	)
GROSS PROFIT		4,501			975,786			-			980,287
OTHER INCOME		98,830			1,298,649			-			1,397,479
OPERATING EXPENSES
General and administrative		(475,762	)		(2,149,306	)		(910,180	)		(3,535,248	)
(LOSS)/PROFIT FROM OPERATIONS		(372,431	)		125,129			(910,810	)		(1,157,482	)
FINANCE COSTS		(8,360	)		(6,848	)		(126	)		(15,334	)
(LOSS)/PROFIT BEFORE TAX		(380,791	)		118,281			(910,306	)		(1,172,816	)
Tax expense		-			(77,207	)		-			(77,207	)
NET (LOSS)/PROFIT	$	(380,791	)	$	41,074		$	(910,306	)	$	(1,250,023	)

	MRNA Scientific			Chemrex Corporation			BGLC			Total
	Nine months ended September 30, 2023
REVENUE	$	28,468		$	7,469,271		$	-		$	7,497,739
COST OF REVENUE		(14,849	)		(6,419,947	)		-			(6,434,796	)
GROSS PROFIT		13,619			1,049,324			-			1,062,943
OTHER INCOME		3,922			507,870			-			511,792
OPERATING EXPENSES
General and administrative		(170,590	)		(2,348,127	)		(1,907,360	)		(4,426,077	)
LOSS FROM OPERATIONS		(153,049	)		(790,933	)		(1,907,360	)		(2,851,342	)
FINANCE COSTS		(2,952	)		(6,794	)		-			(9,746	)
LOSS BEFORE TAX		(156,001	)		(797,727	)		(1,907,360	)		(2,861,088	)
Tax expense		-			(76,418	)		-			(76,418	)
NET LOSS	$	(156,001	)	$	(874,145	)	$	(1,907,360	)	$	(2,937,506	)

	AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023
	Total Assets				Total Liabilities
	2024		2023		2024		2023
BGLC & MRNA Scientific	$	4,027,423		5,002,908	$	469,710	$	176,805
Chemrex Corporation		6,967,632		6,462,614		1,137,172		1,601,002
TOTAL		10,995,055		11,465,522		1,606,882		1,777,807